The document is a regulatory filing containing the unaudited financial results for Q1 FY27 (quarter ended June 30, 2026) and an accompanying investor presentation.
The company reported strong financial performance with revenue of ₹822 Mn (up 9% YoY), Operating EBITDA of ₹191 Mn (up 21% YoY), and PAT of ₹132 Mn (up 22% YoY).
Operating EBITDA margin expanded by 241 basis points YoY to 23.2%, while PAT margin reached 16.0%.
The company maintained a robust cash balance of ₹1,700 Mn despite completing a ₹400 Mn share buyback program.
Jagsonpal completed the acquisition of an 85% controlling stake in Aequitas Healthcare, marking its entry into the hospital supplies business. Aequitas reported FY26 revenue of ₹533 Mn.
Management commentary provided by Manish Gupta, Managing Director and CEO, highlighted outperformance against the Indian pharmaceutical market (18.9% growth vs IPM's 11.6%) and improvement to #88 rank in the IPM.
The company targets ₹100+ Mn EBITDA from Aequitas by Year 2 post-integration, with higher contribution and profitability expected from FY28 onwards.
Key balance sheet items show Shareholders' Funds at ₹2,548 Mn (reduced due to buyback), Financial Assets (Cash & Equivalents) at ₹1,700 Mn, and Net Working Capital at ₹120 Mn.
The presentation included detailed financial tables, brand performance metrics (Top 10 brands constitute ~58% of revenue), and information about the Aequitas acquisition integration progress.
Additional Notes Section
The document includes an investor presentation with comprehensive financial data, operational metrics, and strategic updates.
Financial data was extensively disclosed including income statement, balance sheet items, and brand-level performance details.
The filing was made in compliance with SEBI Listing Obligations and Disclosure Requirement Regulations, 2015 (Regulation 30).
The company contact information and investor relations details are provided for further inquiries.
